Literature DB >> 10716997

Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Z G Wang1, L J Williams, X F Zhang, A Zatorski, V Kudryashov, G Ragupathi, M Spassova, W Bornmann, S F Slovin, H I Scher, P O Livingston, K O Lloyd, S J Danishefsky.   

Abstract

We have previously reported on a carbohydrate-based vaccine program for immunotherapy in cancer patients. One such vaccine, based on the globo H antigen conjugated to the protein keyhole limpet hemocyanin (KLH), has been in clinical evaluation. Although this and other carbohydrate vaccines have been shown to induce antibody responses, there are currently no quantitative data on the antibody levels achieved in immunized patients by these or other anti-cancer vaccines. We report herein an efficient route to complex synthetic oligosaccharides attached to an affinity matrix for identifying and isolating antibodies elicited against such a carbohydrate-based vaccine in humans. Pre- and postvaccination profiles from serum samples of patients immunized with globo H-KLH were compared. All anti-globo H antibody activity was efficiently separated from other serum constituents. The isolated antibodies were readily quantified, and their specificities were analyzed. Since no comparable data were available on antibodies resulting from the vaccination of other cancer patients, we compared the observed levels with those quoted in studies with bacterial polysaccharide vaccines that had been quantified. Remarkably, cancer patients immunized with globo H-KLH produce anti-globo H antibody levels often exceeding those formed by immunization with bacterial polysaccharides. In addition, substantial quantities of both IgG and IgM antibodies were elicited, clearly indicating a class switch to IgG. Taken together, these analyses serve to clarify several aspects of the immune response to the vaccine and give several new insights to the carbohydrate-based vaccination strategy. Furthermore, antibodies so isolated could well have applications in clinical therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716997      PMCID: PMC15996          DOI: 10.1073/pnas.97.6.2719

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines.

Authors:  A Soininen; I Seppälä; T Nieminen; J Eskola; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

Review 2.  Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans.

Authors:  P O Livingston; G Ragupathi
Journal:  Cancer Immunol Immunother       Date:  1997-10       Impact factor: 6.968

Review 3.  Human immunoglobulin subclasses.

Authors:  D E Normansell
Journal:  Diagn Clin Immunol       Date:  1987

4.  Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

5.  Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines.

Authors:  V Kudryashov; H M Kim; G Ragupathi; S J Danishefsky; P O Livingston; K O Lloyd
Journal:  Cancer Immunol Immunother       Date:  1998-02       Impact factor: 6.968

6.  Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.

Authors:  S Zhang; H S Zhang; V E Reuter; S F Slovin; H I Scher; P O Livingston
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

7.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.

Authors:  S Zhang; C Cordon-Cardo; H S Zhang; V E Reuter; S Adluri; W B Hamilton; K O Lloyd; P O Livingston
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

8.  From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  2000-03       Impact factor: 15.336

9.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

10.  Generation of monoclonal antibodies reacting with normal and cancer cells of human breast.

Authors:  S Mènard; E Tagliabue; S Canevari; G Fossati; M I Colnaghi
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

View more
  11 in total

1.  Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen.

Authors:  Cheng-Yuan Huang; Desiree A Thayer; Aileen Y Chang; Michael D Best; Julia Hoffmann; Steve Head; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

2.  Total Synthesis of the Congested, Bisphosphorylated Morganella morganii Zwitterionic Trisaccharide Repeating Unit.

Authors:  D Jamin Keith; Steven D Townsend
Journal:  J Am Chem Soc       Date:  2019-08-01       Impact factor: 15.419

3.  Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.

Authors:  V Kudryashov; P W Glunz; L J Williams; S Hintermann; S J Danishefsky; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.

Authors:  T Gilewski; G Ragupathi; S Bhuta; L J Williams; C Musselli; X F Zhang; W G Bornmann; M Spassova; K P Bencsath; K S Panageas; J Chin; C A Hudis; L Norton; A N Houghton; P O Livingston; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia.

Authors:  Paola Marcato; Thomas P Griener; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Chemoenzymatic Syntheses of Tumor-Associated Carbohydrate Antigen Globo-H and Stage-Specific Embryonic Antigen 4.

Authors:  Zhen Wang; Michel Gilbert; Hironobu Eguchi; Hai Yu; Jiansong Cheng; Saddam Muthana; Luyuan Zhou; Peng George Wang; Xi Chen; Xuefei Huang
Journal:  Adv Synth Catal       Date:  2008-08-04       Impact factor: 5.837

7.  Multi-component one-pot synthesis of the tumor-associated carbohydrate antigen Globo-H based on preactivation of thioglycosyl donors.

Authors:  Zhen Wang; Luyuan Zhou; Kheireddine El-Boubbou; Xin-shan Ye; Xuefei Huang
Journal:  J Org Chem       Date:  2007-07-21       Impact factor: 4.354

Review 8.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

Authors:  Satoshi Nagata; Ira Pastan
Journal:  Adv Drug Deliv Rev       Date:  2009-08-11       Impact factor: 15.470

9.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

10.  A novel Gal(beta1-4)Gal(beta1-4)Fuc(alpha1-6)-core modification attached to the proximal N-acetylglucosamine of keyhole limpet haemocyanin (KLH) N-glycans.

Authors:  Manfred Wuhrer; Marjolein L M Robijn; Carolien A M Koeleman; Crina I A Balog; Rudolf Geyer; André M Deelder; Cornelis H Hokke
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.